OnKure Therapeutics, Inc. Market Cap ($104.89 Million)
Market Cap & Net Worth: OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. market cap. OnKure Therapeutics, Inc. (NASDAQ:OKUR) has a market capitalization of $104.89 Million ($104.89 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18855 globally and #4375 in its home market, demonstrating a -0.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OnKure Therapeutics, Inc.'s stock price $2.59 by its total outstanding shares 40496309 (40.50 Million). Also see OnKure Therapeutics, Inc. cash flow conversion for how efficiently the company converts equity into cash flow.
OnKure Therapeutics, Inc. Market Cap History (2021–2026)
OnKure Therapeutics, Inc. market cap history from 2021 to 2026. Data shows change from $3.46 Billion to $104.89 Million (-51.70% CAGR). Check OKUR stock price for real-time trading data and today's change.
Index Memberships
OnKure Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #523 of 976 |
Weight: OnKure Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OnKure Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OnKure Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore OnKure Therapeutics, Inc. (OKUR) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OKUR by Market Capitalization
Companies near OnKure Therapeutics, Inc. in the global market cap rankings as of November 5, 2026. Also see total assets of OnKure Therapeutics, Inc. for a full breakdown of the balance sheet.
Key companies related to OnKure Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of OnKure Therapeutics, Inc. (2021–2026)
Market capitalization of OnKure Therapeutics, Inc. from 2021 to today. Between 2021 and today, OnKure Therapeutics, Inc.'s market cap moved from $3.46 Billion to $ 104.89 Million, with a yearly change of -51.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $104.89 Million | -10.69% |
| 2025 | $117.44 Million | -66.28% |
| 2024 | $348.27 Million | -46.25% |
| 2023 | $647.94 Million | -31.33% |
| 2022 | $943.56 Million | -72.75% |
| 2021 | $3.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of OnKure Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $104.89 Million USD |
| MoneyControl | $104.89 Million USD |
| MarketWatch | $104.89 Million USD |
| marketcap.company | $104.89 Million USD |
| Reuters | $104.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatmen… Read more